CRVS

9.6703.40%
LS

Linda S. Grais

Independent Director

Dr. Linda S. Grais, also known as Lind, J.D., M.D. is Chair of Iolyx Therapeutics, Inc. Dr. Grais was Director of Iolyx Therapeutics, Inc. She serves as Director of CollectiveHealth, Inc. since April 2023. She serves as an Independent Director of ICON Public Limited Company since July 1, 2021. Dr. Grais has been an Independent Director at Deerfield Healthcare Technology Acquisitions Corp. since July 16, 2020 and Corvus Pharmaceuticals, Inc. since January 28, 2019. Dr. Grais serves as a Consultant to Institute of Medicine. Dr. Grais served as the Chief Executive Officer and President of Ocera Therapeutics, Inc. since June 2012 until 2018 and served as its Secretary until December 11, 2017. She was a Partner and managing member of InterWest Partners since May 2005 until February 2011 and served as its Executive-in-Residence. She serves as a Venture Member of InterWest Management Partners IX, LLC and is General Partner of InterWest Partners IX, LP. She has served as a member of the Board of Directors InterWest Partners since May 2007. She has a wide array of experience as a Physician, attorney and biotechnology entrepreneur. She is Co-Founder of Structural Genomix, Inc. She was Co-Founder of SGX Pharmaceuticals Inc. and served as its Executive Vice President from July 1998 to July 2003. She served as Vice President of Corporate Development of Structural Genomix, Inc. She was Executive Vice President at Structural GenomiX, Incorporated from 1997 until 2004. She served in the Life Sciences Group at Wilson Sonsini Goodrich & Rosati. Dr. Grais served as Corporate Attorney of Wilson Sonsini Goodrich & Rosati from 1993 until 1997, where she represented biotechnology and medical device companies in venture financings, public offerings and strategic partnerships. She served as an Independent Director of PRA Health Sciences, Inc. since October 9, 2015 until July 1, 2021. She serves a Director of Gynesonics, Inc. She is a Member of the Stanford Law School Board of Visitors. She has been an Independent Director of Arca Biopharma, Inc. (formerly known as, ARCA Discovery, Inc.) since May 2007 and served as its Lead Independent Director. She served as a Director at Ocera Therapeutics, Inc. since January 2008 until December 11, 2017. She has been Independent Director at Zosano Pharma Corporation since January 14, 2019. She was an Assistant Clinical Professor in the Department of Internal Medicine and Critical Care at the University of California, San Francisco from 1988 until 1990. She also serves as a board member of several non-profit organizations, including Gladstone Institutes, Research Bridge Partners and Partners Global. She was Assistant Professor in the Dept. of Internal Medicine at the University of California. She received her Bachelor of Laws from Stanford Graduate School of Business, Doctor of Medicine from Yale Medical School and holds BA Magna Cum Laude and Phi Beta Kappa from Yale University. She received her J.D. from Stanford University Law School.

Positions